3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
37
Pancreatic Neoplasms
19
Stomach Neoplasms
16
Colonic Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Burkitt Lymphoma
11
Adenocarcinoma Of Esophagus
11
Rectal Neoplasms
10
Neoplasm Metastasis
10
Esophageal Neoplasms
10
Neoplasms
9
Adenocarcinoma
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Leukemia, Biphenotypic, Acute
5
Cholangiocarcinoma
5
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Lung Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Ovarian Neoplasms
3
Gallbladder Neoplasms
3
Endometrial Neoplasms
3
Advanced Solid Tumors
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Myelodysplastic Syndromes
2
Down Syndrome
2
Colorectal Adenocarcinoma
2
Carcinoma, Renal Cell
2
Interventions
Gemcitabine
7
Cisplatin
7
pembrolizumab
4
durvalumab
3
Oxaliplatin
3
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Capecitabine
2
trametinib
1
tivozanib
1
tislelizumab
1
olaparib
1
Yttrium-90
1
Tegafur
1
Stents
1
S 1 (combination)
1
Radiosurgery
1
Nivolumab
1
Leucovorin
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
Floxuridine
1
Dexamethasone
1
CTLA-4 Antigen
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bile Duct Neoplasms
×
Leucovorin
×
90 days
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts